J., Gaughan, J
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, et al
In addition, peripheral once-daily administration of liraglutide produces a clinically-meaningful degree of body weight loss by reducing energy intake, and as such, liraglutide is also an approved monotherapy for treating obesity 37,38
Studies examine the peptide's ability to maintain endothelium integrity and modulate vascular tone
Obesity rates among adults have more than doubled since 1990, from 7% to 16% in 2022, according to the World Health Organization (WHO)